 |
Research |
Our growing pipeline includes novel investigational medications for the potential treatment of HIV/AIDS, liver disease and cardiovascular and respiratory diseases.
|
At Gilead, we are dedicated to advancing the care of patients suffering from life-threatening diseases worldwide. Our research and development programs currently focus on therapeutics for the potential treatment of HIV/AIDS, liver disease and serious cardiovascular and respiratory conditions. Aztreonam for Inhalation Solution
Potential indication: Cystic Fibrosis Marketing Applications Pending
Elvitegravir
Potential indication: HIV/AIDS Phase III
Darusentan
Potential indication: Resistant Hypertension Phase III
Adentri®
Potential indication: Acute Heart Failure Phase III
Ambrisentan
Potential indication: Idiopathic Pulmonary Fibrosis Phase III
Integrase Fixed-dose Regimen (integrase inhibitor/FTC/TDF/GS 9350)
Potential indication: HIV/AIDS Phase II
GS 9350 (pharmacoenhancer)
Potential indication: HIV/AIDS Phase II
GS 9450 (caspase inhibitor)
Potential indication: Hepatitis C/Fibrosis Phase II
GS 9450 (caspase inhibitor)
Potential indication: Nonalcoholic steatohepatitis Phase II
GS 9190 (polymerase inhibitor)
Potential indication: Hepatitis C Phase II
Cicletanine
Potential indication: Pulmonary Arterial Hypertension Phase II
Tecadenoson
Potential indication: Atrial Fibrillation Phase II
Aztreonam for Inhalation Solution
Potential indication: Bronchietasis Phase II
GS 9310/11 (inhaled fosfomycin/tobramycin)
Potential indication: Cystic Fibrosis Phase II
GS 9411 (epithelial sodium channel blocker)
Potential indication: Pulmonary disease Phase I
CVT 6883
Potential indication: Pulmonary disease Phase I
CVT 3619
Potential indication: Diabetes Phase I
|